Convertible Notes Payable - Schedule of Interest Expenses (Details) - Previously Reported [Member] - DiamiR Biosciences Corp. [Member] - USD ($) |
6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Nov. 30, 2025 |
Nov. 30, 2024 |
May 31, 2025 |
May 31, 2024 |
|
| Schedule of Interest Expenses [Line Items] | ||||
| Interest on notes | $ 25,607 | $ 19,490 | $ 38,508 | $ 23,232 |
| Amortization of discount | 31,550 | 19,349 | $ 43,538 | $ 25,367 |
| Total | $ 57,157 | $ 38,839 | ||
| X | ||||||||||
- Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate amount of interest paid or due on all long-term debt. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|